Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

176
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
176

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Ecnoglutide: First Approvals.

Drugs·2026
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025

相关实验视频

Updated: Jul 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

齐卢科普兰:首次获得批准

Matt Shirley1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|December 13, 2023
PubMed
概括
此摘要是机器生成的。

齐卢科普兰 (Zilbrysq®) 是一种新的C5抑制剂,用于治疗一般化骨髓灰质炎 (gMG). 它已经获得了日本,美国和欧盟的初步批准,用于特定的成年GMG患者群体.

更多相关视频

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.0K
Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure
06:39

Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure

Published on: August 28, 2009

14.1K

相关实验视频

Last Updated: Jul 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.0K
Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure
06:39

Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure

Published on: August 28, 2009

14.1K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 免疫学 免疫学 免疫学
  • 神经学 神经学

背景情况:

  • 一般化肌痛性肌痛症 (gMG) 是一种罕见的自身免疫性疾病,影响神经肌肉结节.
  • 目前对gMG的治疗有局限性,需要新的治疗方法.
  • 补充成分5 (C5) 在gMG的病理生理学中起着至关重要的作用.

研究的目的:

  • 总结一下齐卢科普兰 (Zilbrysq®) 的关键发展里程碑.
  • 要突出监管部门对齐卢科普兰的批准,用于一般化骨髓灰质炎.

主要方法:

  • 对zilucoplan的临床前和临床发展数据的审查.
  • 对监管提交和批准时间表的分析.
  • 关键试验结果和患者群体特征的总结.

主要成果:

  • 齐卢科普兰是一种皮下注射的C5抑制剂,在患有gMG的成年患者中表现出有效性.
  • 日本首次批准 (2023年9月) 用于抗类固醇耐药或免疫抑制剂不耐受的抗乙胆受体 (AChR) 抗体阳性gMG患者.
  • 随后在美国 (2023年10月) 和欧盟 (2023年12月) 对类似患者群体的批准.

结论:

  • 齐卢科普兰在治疗一般化骨髓灰质炎的治疗方面取得了重大进展.
  • 药物的开发和批准里程碑强调了它的治疗潜力.
  • 澳大利亚和加拿大的正在进行的监管审查可能会扩大患者对zilucoplan的获取.